Carver Kyle 4
4 · Evommune, Inc. · Filed Nov 12, 2025
Insider Transaction Report
Form 4
Evommune, Inc.EVMN
Carver Kyle
Chief Financial Officer
Transactions
- Conversion
Common Stock
2025-11-07+3,175→ 75,800 total - Conversion
Series B Preferred Stock
2025-11-07−25,000→ 0 total→ Common Stock (3,175 underlying)
Footnotes (1)
- [F1]Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date.